GLP-1 receptor agonist medications, such as semaglutide (found in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound), have transformed the treatment of obesity and type 2 diabetes by dramatically reducing appetite and promoting significant weight loss. Yet, as users shed pounds rapidly, some develop a gaunt, hollowed-out “anorexic appearance”—sunken cheeks, sagging skin, and an emaciated look often dubbed “Ozempic face” or “Ozempic body.” This post examines the pharmacological drivers of these cosmetic changes, distinguishes them from clinical anorexia nervosa, and evaluates the evidence on whether these drugs are associated with the onset, exacerbation, or misuse in eating disorders. Drawing on medical sources and expert guidance, it offers a balanced view of benefits, risks, and clinical considerations for patients and providers.

Read More